Log In
Print this Print this

DAC HYP, Daclizumab high-yield process (Zinbryta)

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionHumanized mAb against IL-2 receptor alpha chain (CD25)
Molecular Target Interleukin-2 (IL-2) receptor alpha chain (CD25)
Mechanism of ActionBinds interleukin-2 (IL-2) receptor alpha chain (CD25); Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentRegistration
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat relapsing forms of multiple sclerosis (MS); Treat relapsing-remitting multiple sclerosis (RRMS)
Regulatory Designation
PartnerBiogen Inc.;
UCB Group;
UCB Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today